SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

BeneFIX

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 1997.
Why 3/10
BeneFIX is an already-approved, marketed drug with no pending regulatory decision, pivotal readout, or other hard binary catalyst scheduled in the next 12 months. It is a very small part of Pfizer's diversified $63B+ revenue portfolio, so even a material change in its sales would not drive a meaningful share-price move.
Actionable Insight NEUTRAL

BeneFIX is a mature, approved product with no upcoming binary catalysts. The key thing to watch is whether biosimilar competition or gene therapy uptake (CSL's Hemgenix) erodes its market share over time, but this is a slow-moving, non-binary dynamic for a drug that is a tiny fraction of Pfizer's $63B+ revenue base.

Price Chart

Loading chart...

Executive Summary

BeneFIX (nonacog alfa) is a recombinant coagulation factor IX replacement therapy approved by the FDA in 1997 for hemophilia B. Marketed by Pfizer, it is used for on-demand treatment, perioperative management, and routine prophylaxis of bleeding episodes. The drug competes in a crowded hemophilia B market against extended half-life products (Alprolix, Idelvion, Rebinyn), other standard half-life products (Ixinity, Rixubis), and emerging gene therapies (Hemgenix). BeneFIX is a mature, approved product with no upcoming binary catalysts, and it represents a very small fraction of Pfizer's $63B+ annual revenue, making it essentially immaterial to the stock's performance.

How It Works

BeneFIX is a recombinant (lab-made) version of human clotting factor IX, a protein that people with hemophilia B are missing or have too little of. When injected into a vein, it temporarily replaces the missing factor, allowing the blood to clot normally to stop or prevent bleeding episodes.

Trial Status

BeneFIX was FDA-approved on February 11, 1997. Pfizer has conducted post-approval studies including a Phase 3 trial of once-weekly prophylactic dosing (100 IU/kg), which met its primary endpoint with a statistically significant reduction in annualized bleeding rate versus on-demand treatment. Results were published in Haemophilia.

The Two-Sided Case

▲ Bull Case4
BeneFIX is a well-established, FDA-approved therapy with decades of real-world use and a well-characterized safety profile for hemophilia B.
Pfizer published positive Phase 3 data for a once-weekly prophylactic dosing regimen (100 IU/kg), which showed a statistically significant reduction in annualized bleeding rate versus on-demand treatment, potentially extending the product's utility.
The global hemophilia B market is projected to grow from roughly $3.4 billion in 2025 to $4-6 billion by the early 2030s, providing a stable tailwind for established products.
Pfizer's broad commercial infrastructure and patient support programs (Pfizer Hemophilia Connect) help maintain BeneFIX's position in the market.
▼ Bear Case4
Faces intense competition from extended half-life factor IX products (Sanofi's Alprolix, CSL Behring's Idelvion, Novo Nordisk's Rebinyn) that offer less frequent dosing and better bleed protection.
Gene therapy competition is emerging: CSL's Hemgenix is approved for hemophilia B, and Pfizer itself discontinued its own gene therapy Beqvez, signaling the standard half-life replacement market may shrink over time.
As a standard half-life product first approved in 1997, BeneFIX may face biosimilar competition as patents and exclusivity expire, pressuring pricing and market share.
BeneFIX is a very small revenue contributor within Pfizer's $63B+ annual portfolio, so any changes in its sales have negligible impact on Pfizer's stock price.

Upcoming Catalysts

  • No upcoming binary catalysts identified. BeneFIX is a mature approved product with no pending FDA decisions, pivotal readouts, or regulatory actions scheduled.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 12

Hover a chip for the title
1 pfizer.com2 fda.gov3 drugs.com4 fda.gov5 researchandmarkets.com6 fiercepharma.com7 pfizer.com8 drugpatentwatch.com9 static.cigna.com10 stockanalysis.com11 cnbc.com12 ema.europa.eu